NBIX fund manager activity
Neurocrine Biosciences, Inc · Nasdaq. Reported by 6 tracked fund managers in their 13F filings, Q3 2017 to Q2 2026.
Q4 2025
| Manager | Activity | Shares | Value | % of portfolio | Filed |
|---|
| Dodge & Cox Funds | Trimmed | 5,508,042 | $781,205,597 | 0.42% | Feb 13, 2026 |
| Ken Fisher - Fisher Asset Management | Added | 112,242 | $15,919,281 | 0.01% | Feb 9, 2026 |
| Jeremy Grantham - GMO | New | 7,133 | $1,011,673 | 0.00% | Feb 17, 2026 |
| Joel Greenblatt - Gotham Asset Management | Added | 168,572 | $23,908,567 | 0.09% | Feb 17, 2026 |
Q3 2025
| Manager | Activity | Shares | Value | % of portfolio | Filed |
|---|
| Dodge & Cox Funds | Trimmed | 5,556,618 | $780,038,035 | 0.42% | Nov 13, 2025 |
| Ken Fisher - Fisher Asset Management | Added | 94,795 | $13,307,320 | 0.00% | Nov 12, 2025 |
| Joel Greenblatt - Gotham Asset Management | Added | 136,354 | $19,141,375 | 0.08% | Nov 14, 2025 |
Newer quarters · Older quarters